drugset / Trial / NCT07621471
IL-15 Enhanced NK Cell Therapy for Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IL-15 enhanced engineered NK cells | Cell therapy | — | Intravenous |